Abstract:Background The success of allogenic stem cell transplantation in curing AML suggests that the immune system can be harnessed to eradicate AML. In a phase 2 trial (NCT02397720) in relapsed/refractory (R/R) AML patients, we demonstrated that the azacitidine/nivolumab combination improved response rates and median overall survival compared with similar patients treated on other azacitidine-based studies (Daver et al Cancer Discovery 2019). The heterogenous response profiles and shorter duration of responses than seen in solid tumor patients suggested hitherto undefined tumor intrinsic, tumor microenvironment (TME) and T cell factors may impede PD-1 blockade therapy in AML. Methods We performed single cell RNA sequencing (scRNAseq) of 13,633 healthy bone marrow (BM) donor, and 113,394 BM cells from 22 aspirates (8 pre- and 14 post- treatment) from 8 R/R AML patients (median age 73 years; range 64-88 years) treated with azacitidine/nivolumab (Fig 1A). 3/8 patients were responders (2CR, 1 PR), while 2/8 and 3/8 had stable disease (SD), and no response (NR), respectively, allowing us to evaluate factors involved in response, relapse and resistance to azacitidine/nivolumab. Results A total of 60,753 AML and 52,641 TME cells passed scRNAseq quality check, with the proportion of identified AML cells correlating with clinical flow cytometry (r=0.87, p=1.5x10-7) and immunohistochemistry (r=0.73, p=0.0001). Pre- and post-treatment AML cells clustered by patient and had distinct cell cycle profiles regardless of response type, suggesting significant inter-tumor heterogeneity (Fig 1B). In an aggregate analysis of all cells at the pretreatment timepoint, the 3 responders had lower leukemia stemness (LSC17) scores compared with NR (p<2.2x10-16) and SD (p<10-6) patients. Inferred copy number loss of chromosome 7/7q by scRNAseq was consistent with clinical karyotype and was associated with resistance to PD-1 based therapy (Figure 1C). PT3 (CR) had an emergent chromosome 7q deletion after 6 months on treatment, which preceded the clinical relapse. To further explore whether deletion 7/7q was associated with resistance to PD1-blocakde-based therapy, we evaluated 57 R/R AML patients treated on azacitidine/nivolumab with available pretreatment cytogenetic profiling. Only 10.5% (2/19) patients with deletion 7/7q achieved a CR/CRI to azacitidine/nivolumab compared with 36.8% (14/38) of patients without the deletion (p=0.03) (Fig 1D). To decouple azacitidine from nivolumab effect, we evaluated an independent cohort of R/R AML (n=99) treated on azacitidine-based studies without immune checkpoint blockade (ICB) and found no such correlation, suggesting that deletion 7/7q induced resistance may be primarily in PD-1 blockade therapy setting (Fig 1E). IFNgpathway genes were enriched (q<0.0005) in chromosome 7q region indicating that IFNg pathway loss may modulate resistance to ICB based therapies in AML. Pathway enrichment revealed AML cells with higher oxidative phosphorylation, reactive oxygen species and glycolytic/metabolic pathways were more likely to be resistant to PD-1 blockade-based therapy (Fig 1F). On paired single cell TCR analysis from 4,742 and 26,095 T cells from healthy and R/R AML BMs, respectively, T cells in the TME of AML patients had less clonal diversity and more oligoclonal dominance compared to healthy BMs (Fig 1G-H). Following treatment 76.9% and 72.4% of novel and expanded clones were contributed by responders, with non-responders contributing only 5% and 3.4% of the novel and expanded clones, respectively (Fig. 1I). Among responders, the majority of clones were either novel or expanded, whereas NR had mostly contracted clones. Conclusions: This is one of the first studies examining the effect of PD-1 blockade at single cell resolution in a hematologic malignancy. Further, this is the largest single study analyzing single AML cells longitudinally. AML cells harboring deletion 7/7q loss, enriched for LSC signature and metabolic/oxidative pathways, were features associated with resistance to azacitidine/nivolumab therapy. Azacitidine/nivolumab induced novel and expanded T cell clonotypes primarily in responders. Disentangling AML cells from their complex microenvironment revealed characteristics that shaped resistance to ICB-based therapy and could inform strategies to target AML vulnerabilities. Disclosures DiNardo: Takeda: Honoraria; Novartis: Consultancy; AbbVie: Consultancy, Honoraria, Research Funding; Syros: Honoraria; MedImmune: Honoraria; Jazz: Honoraria; Agios: Consultancy, Honoraria, Research Funding; ImmuneOnc: Honoraria; Daiichi Sankyo: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Calithera: Research Funding; Notable Labs: Membership on an entity's Board of Directors or advisory committees. Kadia:Pfizer: Honoraria, Research Funding; Cyclacel: Research Funding; Incyte: Research Funding; Novartis: Honoraria; Abbvie: Honoraria, Research Funding; Astellas: Research Funding; Cellenkos: Research Funding; Ascentage: Research Funding; Amgen: Research Funding; JAZZ: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Astra Zeneca: Research Funding; Celgene: Research Funding; Genentech: Honoraria, Research Funding; Pulmotec: Research Funding. Ravandi:Celgene: Consultancy, Honoraria; Orsenix: Consultancy, Honoraria, Research Funding; Macrogenics: Research Funding; Astellas: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Xencor: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding. Borthakur:Xbiotech USA: Research Funding; BioLine Rx: Research Funding; PTC Therapeutics: Consultancy; BioLine Rx: Consultancy; Incyte: Research Funding; Novartis: Research Funding; Jannsen: Research Funding; Abbvie: Research Funding; Cyclacel: Research Funding; Argenx: Consultancy; FTC Therapeutics: Consultancy; Treadwell Therapeutics: Consultancy; PTC Therapeutics: Research Funding; Polaris: Research Funding; BMS: Research Funding; Oncoceutics: Research Funding; Nkarta Therapeutics: Consultancy; BioTherix: Consultancy; GSK: Research Funding; Curio Science LLC: Consultancy; AstraZeneca: Research Funding. Konopleva:Ascentage: Research Funding; Eli Lilly: Research Funding; Rafael Pharmaceutical: Research Funding; Forty-Seven: Consultancy, Research Funding; Ablynx: Research Funding; Amgen: Consultancy; F. Hoffmann La-Roche: Consultancy, Research Funding; AstraZeneca: Research Funding; AbbVie: Consultancy, Research Funding; Calithera: Research Funding; Reata Pharmaceutical Inc.;: Patents & Royalties: patents and royalties with patent US 7,795,305 B2 on CDDO-compounds and combination therapies, licensed to Reata Pharmaceutical; Kisoji: Consultancy; Cellectis: Research Funding; Sanofi: Research Funding; Genentech: Consultancy, Research Funding; Stemline Therapeutics: Consultancy, Research Funding; Agios: Research Funding. Garcia-Manero:Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Jazz Pharmaceuticals: Consultancy; Acceleron Pharmaceuticals: Consultancy, Honoraria; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Amphivena Therapeutics: Research Funding; Novartis: Research Funding; AbbVie: Honoraria, Research Funding; H3 Biomedicine: Research Funding; Onconova: Research Funding. Green:KDAc Therapeutics: Current equity holder in private company. Sharma:Achelois: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Apricity Health: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; BioAlta: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Codiak BioSciences: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Constellation: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Dragonfly Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Forty-Seven Inc.: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Hummingbird: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; ImaginAb: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Jounce Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Lava Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Lytix Biopharma: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Marker Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Oncolytics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Infinity Pharma: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; BioNTech: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Glympse: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Polaris: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees. Allison:Achelois: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Apricity Health: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; BioAlta: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Codiak BioSciences: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Dragonfly Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Forty-Seven Inc.: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Hummingbird: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; ImaginAB: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Jounce Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Lava Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Lytix Biopharma: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Marker Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Polaris: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; BioNTech: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees. Daver:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trillium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syndax: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Fate Therapeutics: Research Funding; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Servier: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novimmune: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Trovagene: Research Funding; ImmunoGen: Research Funding; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Abstract:Chronic lymphocytic leukaemia (CLL) is characterized by extensive genetic heterogeneity. Mutations in TP53 are associated with refractoriness to chemoimmunotherapy. Although new therapies have improved clinical outcomes in this group of patients, many patients eventually relapse. Several studies using high throughput sequencing have identified novel genetic mutations with prognostic significance in CLL (Wang et al, 2011). However, there has not been a systematic effort to identify high priority, targetable mutations for which pharmaceuticals already exist for other indications, or for which pharmaceuticals are already in development. We performed a retrospective analysis of CLL patients who underwent next generation sequencing (NGS) of tumour samples obtained from peripheral blood and bone marrow sources. We describe our findings in which we identify potentially targetable somatic mutations that may inform future clinical trial design. In particular, our results highlight the occurrence of mutations in BRAF as a potential target in CLL management. A total of 122 sequential patients with CLL who underwent NGS were identified from our clinical database. NGS was performed on an Illumina MiSeq (Illumina, Inc., San Diego, CA, USA) using a custom 68-gene amplicon-based panel developed at our centre with a detection limit of 5% allele frequency and a minimum depth of coverage of 250×. We used a custom bioinformatics pipeline, combining open source tools and custom algorithms for analysis (Daber et al, 2013; Sehgal et al, 2015). All mutational events in the coding regions were classified as pathogenic, benign polymorphisms or variants of uncertain significance. We defined pathogenic mutations as those that alter protein function in a way that drives tumourigenesis with functional evidence showing that the mutation is associated with disease. Benign polymorphisms are defined as those that have an allele frequency >0.1% in the general population as reported in the Exome Variant Server (EVS) and Exome Aggregation Consortium (ExAC) databases (http://evs.gs.washington.edu/EVS/ http://exac.broadinstitute.org/ ). Variants of uncertain significance were defined as those mutational events that did not meet the definition of pathogenic or benign polymorphism. Seventy-two patients (59%) had at least one pathogenic mutation (range of 1–8 mutations). Pathogenic mutations were found in 27 genes, with the top five (TP53, SF3B1, ATM, NOTCH1 and BRAF) affecting 62 patients and these represented 64% of the pathogenic mutational events. Sixty-two patients were found to have pathogenic mutations in genes for which targeted therapeutic agents exist, i.e. those having shown efficacy, either in preclinical in vivo models or in the clinical setting. Pathogenic mutations in NOTCH1, ATM, BRAF and XPO1 were the most frequently implicated targetable mutations in our cohort (Fig 1). Among the most common mutations found in our cohort, mutations in BRAF are the most readily targeted given currently available pharmaceuticals. In contrast to the limited experience in targeting malignancies with NOTCH1, ATM and XPO1 mutations, BRAF inhibition has not only transformed the treatment of BRAF-mutated melanoma, but has also been successfully employed in other malignancies. Both the frequency of its occurrence in CLL, and efficacy in different malignancies supports the rationale for clinical trial design in BRAF inhibition in CLL. Among the seven patients affected, four different amino acid changes were identified in BRAF: V600E, K601E, D594G and D594N. The BRAF V600E mutation is well documented to have oncogenic activity in papillary thyroid cancers, melanomas and hairy cell leukaemia (Li et al, 2009; Wellbrock & Hurlstone, 2010), and it results in the constitutive activation of BRAF kinase activity. BRAF V600E is found in nearly all cases of hairy cell leukaemia (HCL), and the BRAF inhibitor vemurafenib has already been shown to be clinically active in relapsed-refractory HCL (Dietrich et al, 2012; Samuel et al, 2014). The BRAF K601E mutation, like V600E, is also an activating mutation associated with the RAF/MEK/Erk pathway. Preclinical and clinical evidence suggest that BRAF inhibition with vemurafenib and MEK inhibition with trametinib can block downstream signalling induced by the K601E mutation (Dahlman et al, 2012; Kim et al, 2013). The remaining BRAF mutations are both D594 inactivating mutations, against which BRAF inhibitors are not expected to be effective. The mechanism through which BRAF D594 inactivating mutations may contribute to oncogenesis has been elucidated (Heidorn et al, 2010). In the presence of activated RAS, inactivated BRAF can form a complex with CRAF, resulting in the hyperactivation of MEK. Choosing inhibitors of the downstream targets RAS and MEK may be more appropriate. In the absence of concomitant RAS activation, inactivated BRAF may still drive oncogenesis through its interaction with CRAF and may be amenable to treatment with pan-RAF inhibition, such as with sorafenib. In our cohort, 6 of 7 patients with a pathogenic mutation in BRAF had co-occurring mutations. These included mutations in ATM, TP53, XPO1, KRAS, NRAS, NOTCH1, NF1, TET2, BCOR, IDH2, SF3B1 and BIRC3. One patient had concomitant pathogenic mutations in BRAF and NRAS, which is notable because in melanoma, NRAS and BRAF mutations are mutually exclusive, whereas mutations in BRAF and PTEN frequently co-occur (Wellbrock & Hurlstone, 2010). The former is reflective of the fact that NRAS is upstream of BRAF, and the latter illustrates the interaction between the two distinct RAS signalling streams involving the ERK/MAPK and the PI3K/PTEN/AKT pathways. Just as an NRAS mutation activates both signalling streams driving cellular proliferation, concurrent activation of BRAF with loss of PTEN cooperate to effect signalling in both pathways. The co-occurrence of BRAF and NRAS mutations in our patient means that both RAS signalling pathways are affected. This finding highlights the importance of looking at co-occurring mutations prior to selecting targeted pharmaceuticals. Given the genetic heterogeneity of CLL and our characterization of targetable mutations, we believe that mutation-specific clinical trial design in CLL may yield invaluable insight into alternative therapeutic approaches, particularly in patients who have failed chemoimmunotherapy combinations and novel kinase inhibitors. The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) clinical trial (NCT02465060) seeks to assign treatment to patients based on tumour molecular abnormalities rather than specific disease type. Given our findings and the diversity of pathways involved in CLL biology, we believe that CLL is a candidate disease entity for the design of clinical trials using a precision medicine approach that selects therapies based on individual patient genetic profiles. J.W. Performed research, analyzed data, wrote the paper. J.M. Performed NGS, analyzed data, edited the paper. D.B.L. Performed NGS, analyzed data, edited the paper. C.T. Analyzed data, wrote the paper. S.J.S. Analyzed data, wrote the paper. A.R.M. Designed research, performed research, analyzed data, wrote the paper. Wang: No relevant conflicts of interest. Morrissette: No relevant conflicts of interest. Lieberman: No relevant conflicts of interest. Timlin: No relevant conflicts of interest. Schuster: Nordic Nanovector: Membership on an entity's Board of Directors or advisory committees; Janssen: Research Funding; Novartis: Research Funding; Genentech: Consultancy; Gilead: Research Funding; Hoffman-LaRoche: Research Funding; Celgene: Consultancy, Research Funding; Phamacyclics: Consultancy, Research Funding. Mato: Gilead: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Pronai Pharmaceuticals: Research Funding; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy; Celgene Corporation: Consultancy, TG Therapeutics: Research Funding; Acerta: Research Funding.

Disease Characteristics of AML Patients with Germline DDX41 Variants

Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience

Abstract A037: Investigating the role of the somatic DDX41 variant in the context of DDX41 hereditary myeloid malignancy syndromes (HMMS)

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome

Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/ KMT2A -Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms

Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)

Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis

Dead/H-Box Helicase 11 (DDX11) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice

Creating a Variant Database for the American Society of Hematalogy by Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis

Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations in Chronic Lymphocytic Leukaemia

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines